Epithelial ovarian carcinoma: Current evidences and future perspectives in the first-line setting

Clinical and Translational Oncology

Volumn 12, Issue 6, 2010, Pages 418-430

  González Martín, Antonio ^a   Toledo, Gemma ^a   Chiva, Luis ^a  

^a MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Advanced ovarian carcinoma; Chemotherapy; Early stage ovarian carcinoma; Epithelial ovarian cancer; Evidence based medicine; First line therapy; Pathology; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE; BETA CATENIN; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; MUCIN 2; MUCIN 5AC; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROTEIN P53; TAXANE DERIVATIVE; TOPOTECAN; TRANSCRIPTION FACTOR CDX2; UNINDEXED DRUG; WT1 PROTEIN;

ABDOMINAL PAIN; ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM BIOPSY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SALPINGOOOPHORECTOMY; SPECIALIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADJUVANT THERAPY; ANIMAL; CARCINOMA; EVIDENCE BASED PRACTICE; FEMALE; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; TRENDS;

ANIMALS; CARCINOMA; EVIDENCE-BASED PRACTICE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 77955957021     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0529-1     Document Type: Review

References (56)

1. Jemal A, Siegel R, Ward E et al (2010) Cancer statistics 2009. CA Cancer J Clin 59:225-249
2. Goff BA, Mandel Lynn, Muntz HG, Melacon CH (2004) Ovarian carcinoma diagnosis. Results of a Frecuency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705-2712
3. Vergote I, De Brabanter J, Fyles A et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian cancer. Lancet 357:176-182
4. Trimbos JB, Parmar M, Vergote I et al (2003) International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Nat Cancer Inst 95:105-112
5. Hennessy BT, Coleman R, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371-1382
6. Poveda A, Casado A, Cervantes A et al (2007) Treatment guidelines in ovarian cancer. Clin Transl Oncol 9:308-316
7. Gonzalez-Martin A (2005) Treatment of recurrent disease: randomized trials of monotherapy versus combination therapy. Int J Gynecol Cancer 15(Suppl 3):241-246
8. Medeiros LR, Rosa DD, Bozetti MD et al (2009) Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev Apr 15(2):CD00475
9. Medeiros LR, Rosa DD, Bozetti MD et al (2008) Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev Oct 8(4):CD005344
10. Tavassoli FA, Devilee P eds (2003) World Health Organization Classification of Tumours. Pathology and genetics of tumours of breast and female genital organs. IARC Press, Lyon
11. Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7-15
12. Movahedi-Lankarani S, Baker PM, Gilks CB et al (2009) Protocol for the examination of specimens from patients with carcinoma of the ovary. College of American Pathologists (CAP) Cancer Protocols. Available at http://www.cap.org/ apps/docs/committees/cancer/cancer-protocols/2009/Ovary-09protocol.pdf. Accessed on May 30, 2010
13. McCluggage WG (2008) My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 61:152-163
14. Soslow RA (2008) Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27:161-174
15. Malpica A, Deavers MT, Tornos C et al (2007) Interobserver and intraobserver variability of a twotier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168-1174.
16. Baker PM, Oliva E (2005) Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol 24:39-55
17. Prat J (2005) Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol 18(Suppl 2):S99-S111
18. Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40:1213-1223
19. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428
20. Clement PB (2005) Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Mod Pathol 18(Suppl 2): S113-S129
21. McCluggage WG, Wilkinson N (2005) Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 47:231-247
22. Young RH (2007) From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14:149-177
23. Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518
24. Kurman RJ, Shih Ie M (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151-160
25. Vang R, Shih Ie M, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267-282
26. Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a roposed unifying theory. Am J Surg Pathol 34:433-443
27. Bell J, Brady M, Lage J et al (2003) A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 88:156
28. du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115:1234-1244
29. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis. J Clin Oncol 20:1248-1259
30. du Bois A, Reuss A, Harter P et al (2010) Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733-1739
31. Earle CC, Schrag D, Neville BA et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172-180
32. Du Bois A, Quinn M, Thigpen T et al (2005) 2004 Consensus statements on the management of ovarian cancer - final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16(Suppl)8:7-12
33. du Bois A, Lück H-J, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1330
34. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 21:3194-3200
35. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-arboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691
36. Vergote et al (2008) EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage III-IV ovarian, fallopian tube and peritoneal cancer. Personal communications at the 12th meeting of the International Gynecologic Cancer Society (IGCS) Bangkok, Thailand 2008
37. Martinek I, Kehoe S (2010) When should surgical cytoreduction in advanced ovarian cancer take place? J Clin Oncol doi: 10.1155/2010/852028
38. van der Burg MEL, van Lent M, Buyse M et al (1995) The effect of debulking surgery afterinduction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynaecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. NEJM 332:629-634
39. Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. NEJM 351:2489-2497, 2567
40. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P (2009) Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. Gynecol Oncol 112:257-264
41. Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis. Gynecol Oncol 103:1070-1076
42. Bookman Michael A, Brady Mark F, McGuire William P et al (2009) Evaluation of new platinum- based treatment regimens in advanced-stage ovarian cancer: a phase iii trial of the Gynecologic Cancer InterGroup. J Clin Oncol 27:1419-1425
43. González-Martín A (2007) Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: A new standard in patient care? Clin Transl Oncol 9:409-411
44. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955
45. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007
46. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
47. Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-993
48. Wenzel LB, Huang HQ, Armstrong DK et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: aGynecologic Oncology Group study. J Clin Oncol 25:437-443
49. Walker JL, Armstrong DK, Huang HQ et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 100:27-32
50. Ozols RF, Bookman MA, Young RC et al (2006) Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103:1-6
51. Gore M, du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24:4528-4530
52. Katsumata N, Yasuda M, Takahashi F et al, for the Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374(9698):1331-1338
53. 2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195-198
54. Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621-3627
55. Sánchez-Muñoz A, Pérez-Ruiz E, Mendiola Fernández C, Alba Conejo E, González-Martín A (2009) Current status of anti-angiogenic agents in the treatment of ovarian carcinoma. Clin TranslOncol 11:589-595
56. González Martín A (2009) Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed. Clin Transl Oncol 11:559-560